O’Melveny & Myers, Willkie Farr & Gallagher, Walkers Global and Zhong Lun Law Firm are advising NYSE-listed Chinese clinical research organization WuXi PharmaTech on its agreement to be bought by a Chinese investor consortium for $3.3 billion.

The various buyers are being represented by Wilson Sonsini Goodrich & Rosati, P.C., Sullivan & Cromwell, Weil, Gotshal & Manges, Fangda Partners and Conyers, Dill and Pearman.

WuXi has become the latest Chinese company to exit the U.S. stock market, after announcing that it had agreed officially merge with New WuXi Life Science Limited and its subsidiary WuXi Merger Limited, which were created by a group of investors and executives including CEO Ge Li.

Kurt Berney, a partner in the firm’s Shanghai and San Francisco offices, led the O’Melveny team.

Related Articles

Other News

Mayer Brown, OMM advise on Shanghai Haohai’s $302 mln HK IPO

by Kanishk Verghese |

Mayer Brown JSM and O’Melveny & Myers have advised on biomedical materials maker Shanghai Haohai Biological Technology Co’s $302 million IPO on the Hong Kong Stock Exchange.

Deals

Plethora of U.S., PRC firms on $3.3 bln WuXi PharmaTech take-private deal

by Eileen Ang |

O’Melveny & Myers, Willkie Farr & Gallagher, Walkers Global and Zhong Lun Law Firm are advising NYSE-listed Chinese clinical research organization WuXi PharmaTech on its agreement to be bought by a Chinese investor consortium for $3.3 billion.

Deals

PH, OMM on China Media Capital JV with Warner Brothers

by Shangjing Li |

Paul Hastings and O’Melveny & Myers have scored key advisory roles in private equity firm China Media Capital’s newly formed joint venture with media giant Warner Brothers.